Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Globus Medical (GMED)

Globus Medical Q2 2025 sales rise 18.4% to $745.3 million; full-year guidance reaffirmed

Positive Impact 3 of 5 earnings Written later

Globus Medical reported second-quarter 2025 net sales of $745.3 million, up 18.4% from a year earlier, and GAAP net income of $202.8 million, compared with $31.8 million in the prior-year quarter. GAAP net income was lifted by a $110.6 million bargain purchase gain and a $34.8 million tax benefit, while the company reaffirmed its 2025 revenue and non-GAAP EPS guidance, so shareholders see a strong quarter whose GAAP profit is inflated by one-time items.

Key points

  • Q2 2025 net sales were $745.3 million, up 18.4% as reported and 17.6% on a constant currency basis.
  • The GAAP results include a $110.6 million bargain purchase gain and a $34.8 million tax benefit from a valuation allowance release.
  • The company reaffirmed 2025 revenue guidance of $2.80 billion to $2.90 billion and non-GAAP diluted EPS guidance of $3.00 to $3.30.

The filing

CompanyGlobus Medical (GMED)
Form8-K, current report
Filed with the SECAug 7, 2025, 4:23 PM ET
Accession number0001562762-25-000198

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.